Claybrook Capital, LLC Abb Vie Inc. Transaction History

Claybrook Capital, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 20, 2022	BUY	$107.43 - $135.93 $195,200 - $246,984	1,817 New	1,817 $246,000
Q3 2021 Nov 15, 2021	SELL	$106.4 - $120.78 $1.23 Million - $1.4 Million	-11,601 Closed	0 $0
Q2 2021 Jul 26, 2021	BUY	$105.21 - $117.21 $1.22 Million - $1.36 Million	11,601 New	11,601 $1.31 Million
Q1 2019 May 15, 2019	SELL	$77.14 - $90.79 $4.78 Million - $5.63 Million	-62,003 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$77.85 - $96.01 $4.7 Million - $5.8 Million	60,403 Added 3775.19%	62,003 $5.72 Million
Q1 2018 May 11, 2018	BUY	$92.01 - $123.21 $36,804 - $49,284	400 Added 33.33%	1,600 $151,000
Q4 2017 May 08, 2018	BUY	$89.56 - $98.21 $107,472 - $117,851	1,200	1,200 $116,000

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Claybrook Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Claybrook Capital, LLC with notifications on news.